Shanghai Medicilon Inc.

  On July 12, the 2021 "Top 20 CXO (including CDMO) Enterprise in China" selected by Menet was officially released, which once again demonstrated the professionalism and influence of a strong enterprises in China's pharmaceutical industries. Shanghai Medicilon Inc. (Medicilon) was listed in the "Top 20 CXO (including CDMO) Enterprises in China".  This is the 4th consecutive year that Medicilon has won this honor. It is understood that the "Top 100 List of China's Pharmaceutical Industry" has become one of the most concerned and authoritative pharmaceutical rankings in China for more than 10 consecutive years. Reference: Medicilon's CDMO Service Platform Top 10 Global CDMO Enterprises Medicilon was Awarded The "Golden Horse Award-2021 Best Preclinical CRO/CDMO Enterprise" Medicilon was listed in the "Top 20 CXO (including CDMO) Enterprises in China", which is the inevitable result of Medicilon's 18 years of rooting in new

  ❖  Contract Research Organization CRO Contract Research Organization, referred to as CRO, mainly provides drug discovery, preclinical research, clinical trials and other new drug R&D contract research services for multinational pharmaceutical companies and pharmaceutical companies. At present, biomedical R&D outsourcing has gradually become an indispensable link in the pharmaceutical industry chain and plays an important role in the industrial structure. ❖      Medicilon’s Preclinical Research Services Medicilon is a Preclinical Research Outsourcing (CRO) company. With our more than 10 years experience on preclinical research services, we dedicated to provide our clients with customized preclinical services program in drug metabolism, pharmacokinetics, efficacy studies, and toxicology. We provide our clients a high-quality data and rapid turnaround time to support their drug development, preclinical studies and clinical research and to help them to select the most valuable dr

  To date, there are few literature reports that summarize PROTAC metabolism studies. Therefore, in this article, we share some examples of DMPK studies of   PROTAC   with the experience of the Medicilon   DMPK   department and hope to be helpful to all researchers who are interested in PROTAC molecular DMPK. Prostate cancer is a common malignancy in men, and the development of effective therapies for prostate cancer has been a primary focus of scientific research. The prostate is an androgen-dependent organ, and prostate cancer is an androgen-dependent disease. Androgen action is mediated by the androgen receptor (AR), a hormone-activated transcription factor that belongs to the nuclear receptor superfamily of steroid receptors. AR and its downstream signaling play a vital role in the development and progression of localized and metastatic prostate cancer. Androgen receptor (AR) structure  [1] The primary treatment for metastatic prostate cancer is androgen deprivation therapy (ADT).

  01 Characteristics of ADC drugs The design idea of ADC drugs is to couple antibodies with cytotoxic drugs, so as to simultaneously exert the high specificity of antibodies and the high toxicity of cytotoxic small molecules. The powerful cell-killing ability of poisonous drugs concentrates on tumor cells and reduces the toxic and side effects of normal tissues. ADC drug consists of three parts: monoclonal antibody, linker and cytotoxic small molecule drug. Small molecule drugs are linked to monoclonal antibodies through coupling chains. ADC drugs rely on the specificity and targeting of monoclonal antibodies to tumor cell-associated antigens to reach tumor cells and enter cells through endocytosis. The coupling chain has a low intracellular pH value Or break down under the action of lysosomal proteins to release cytotoxic drugs. The emergence of ADC drugs fills the gap between antibody drugs and traditional chemotherapeutic drugs, increasing the specificity of drugs and improving the

  ADC drugs   are mainly used in the field of anti-tumor, which is one of the hot research directions in recent years. ADC is composed of three parts: monoclonal antibody (mAb), coupling chain (linker) and cytotoxic small molecule (cytotoxin/payload). tumor lesions. Compared with traditional chemical drugs and biological drugs, the safety and effectiveness are significantly improved. The ADC field has made great progress in the past 10 years, and the therapeutic window has continued to expand. According to the forecast of Evaluate Pharma and BCG, the global ADC market is expected to reach US$12.9 billion in 2024, with a compound annual growth rate of about 35% from 2018 to 2024. 01   Global ADC drugs and market analysis In the past year, foreign antibody-conjugated drugs (ADCs) have been hot spots. In September last year, Gilead acquired the ADC company Immunomedics at a premium of 108% and a total value of 21 billion US dollars, triggering an acquisition no less than 11.9 billion US d